GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vistagen Therapeutics Inc (NAS:VTGN) » Definitions » Operating Margin %

Vistagen Therapeutics (Vistagen Therapeutics) Operating Margin % : -1,918.25% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Vistagen Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Vistagen Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-7.88 Mil. Vistagen Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.41 Mil. Therefore, Vistagen Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -1,918.25%.

The historical rank and industry rank for Vistagen Therapeutics's Operating Margin % or its related term are showing as below:

VTGN' s Operating Margin % Range Over the Past 10 Years
Min: -4287.38   Med: -1215.54   Max: 26109.25
Current: -3250.43


VTGN's Operating Margin % is ranked worse than
84.17% of 1030 companies
in the Biotechnology industry
Industry Median: -168.78 vs VTGN: -3250.43

Vistagen Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Vistagen Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-7.88 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-33.90 Mil.


Vistagen Therapeutics Operating Margin % Historical Data

The historical data trend for Vistagen Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vistagen Therapeutics Operating Margin % Chart

Vistagen Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1,645.32 -4,287.38 26,109.25

Vistagen Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,425.56 -6,954.55 -3,931.46 -2,438.85 -1,918.25

Competitive Comparison of Vistagen Therapeutics's Operating Margin %

For the Biotechnology subindustry, Vistagen Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistagen Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Operating Margin % falls into.



Vistagen Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Vistagen Therapeutics's Operating Margin % for the fiscal year that ended in Mar. 2023 is calculated as

Operating Margin %=Operating Income (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=-59.268 / -0.227
=26,109.25 %

Vistagen Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-7.884 / 0.411
=-1,918.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vistagen Therapeutics  (NAS:VTGN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Vistagen Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Vistagen Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vistagen Therapeutics (Vistagen Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Executives
Joshua S. Prince officer: Chief Operating Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Cynthia Lynn Anderson officer: CHIEF FINANCIAL OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Jerry B Gin director 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Reid G. Adler officer: CHIEF LEGAL OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94090
Shawn Singh director, officer: CHIEF EXECUTIVE OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Eg, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Bong Y Koh 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Co-investment Holdings Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Nimish P Shah 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036

Vistagen Therapeutics (Vistagen Therapeutics) Headlines

From GuruFocus